Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Allogeneic osteoblastic cell therapy - BioSenic

Drug Profile

Allogeneic osteoblastic cell therapy - BioSenic

Alternative Names: ALLOB; ALLOB implantation; ALLOB-OP; Allogeneic-osteoblastic-cells-BioSenic

Latest Information Update: 30 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bone Therapeutics
  • Developer BioSenic
  • Class Mesenchymal stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Osteogenesis imperfecta; Osteonecrosis
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Fracture; Intervertebral disc degeneration
  • Discontinued Osteoporosis

Most Recent Events

  • 19 Jun 2023 A phase IIb trial in Fracture has been suspended in Belgium, Czech Republic, France, Germany, Hungary, Poland and Spain
  • 03 Apr 2023 Bone Therapeutics completes enrolment in ALLOB-TF2 phase IIb trial for Fracture in Spain, Poland, Hungary, Germany, France, Czech Republic, Belgium (Intraosseous) (NCT04432389) (EudraCT2018-001054-96)
  • 25 Oct 2022 Medsenic has been acquired by Bone Therapeutics and the later changed its name to BioSenic
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top